ReviewHuman vaccines & immunotherapeutics2023
Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence.
Review in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Trial
- Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.Human vaccines & immunotherapeutics · 2024Trial
- Herpes zoster hospitalization burden in Spain during the initial period of recombinant zoster vaccine implementation.Human vaccines & immunotherapeutics · 2026Article
- Vaccination considerations in autoimmune rheumatic diseases.Nature reviews. Rheumatology · 2026Review
- The epidemiological impact and effectiveness of herpes zoster vaccination among older and pharmacologically immunocompromised adults: a population-based observational study.The Lancet regional health. Western Pacific · 2026Article
- Muscle-targeting LNP vaccines enable potent immune responses against varicella zoster virus.Drug delivery and translational research · 2026Article
- Comparison of Vaccine Adverse Events Between Zoster Vaccine Live and Recombinant Zoster Vaccine: A Prospective Multicenter Survey.Journal of Korean medical science · 2026Article
- Italian recommendations for the diagnosis and treatment of myasthenia gravis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Herpes Zoster Vaccine Uptake Among United States Adults With Rheumatic Disease: A Mixed-Methods Analysis.ACR open rheumatology · 2026Article
- Integrated Western and Traditional Chinese Medicine Approaches for Herpes Zoster and Post-Herpetic Neuralgia: A Narrative Review.Drug design, development and therapy · 2026Review
- Transient Increased Risk of Shingles Post-Shingrix Vaccination: Self-Controlled Case-Series Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases.The Journal of infectious diseases · 2025Article
- Effectiveness of Recombinant Herpes Zoster Vaccine in the U.S. Medicare Population, 2018 to 2019, by Immunocompetence and Prior Receipt of Live Zoster Vaccine.Annals of internal medicine · 2025Article
- Real-world study: Analysis of post-marketing safety for recombinant zoster vaccine in Shandong, China.Human vaccines & immunotherapeutics · 2025Article
- Risk of autoimmune disease flares after recombinant zoster vaccine: A vaccine safety analysis based on the Vaccine Adverse Event Reporting System database.Human vaccines & immunotherapeutics · 2025Article
- Antiviral Inactivated Vaccines: Looking to the Past to Face the Future-A Narrative Review.Vaccines · 2025Review
- Article
- Article
- Review
- Knowledge, Attitudes, and Practices Regarding Herpes Zoster Vaccination Among Primary Healthcare Physicians: A Cross-sectional Survey in Jazan, Saudi Arabia.Oman medical journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recombinant zoster vaccine (RZV) was licensed in the US for prevention of herpes zoster (HZ) in 2017. We conducted a literature search (January 1, 2017-August 1, 2023) using PubMed, Embase, and Scopus to consolidate the real-world evidence related to RZV. Overall, RZV effectiveness against HZ was high across the studied populations in real-world settings, including adults aged ≥ 50 years and patients aged ≥ 18 years with immunodeficiency or immunosuppression. Effectiveness was higher with two doses versus one dose, especially in elderly people and immunocompromised individuals. The safety profile of RZV was broadly consistent with that established in clinical trials. RZV does not appear to increase the risk of disease flares in patients with immune-mediated diseases. Approximately two-thirds of individuals received a second RZV dose within 2-6 months after the first dose. Collectively, RZV effectiveness against HZ was high, and these real-world studies reaffirm its favorable benefit-risk profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.